GlassScriptPhysician profile
James M Rossetti
NPI 1982600425
$24,688.07
in general payments reported to CMS, 2019-2025
13 companies · $9,360 in 2025
The $9,360 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $12.45 · 2021: $22.24 · 2022: $5,830 · 2023: $7,730 · 2024: $1,497 · 2025: $9,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,250 · Food and Beverage: $267 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,985.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,250.00 |
| Food and Beverage | $266.50 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $9,333.62 | 2025 | |
| Cti Biopharma Corp. | $8,592.04 | 2022-2023 | Vonjo |
| Abbvie INC. | $3,477.08 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,877.92 | 2019-2023 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $183.99 | 2019-2023 | Imbruvica |
| Beigene USA, INC. | $162.38 | 2022-2024 | Brukinsa |
| Beone Medicines USA, INC. | $26.35 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $22.24 | 2021 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rossetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.